ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer
August 24 2016 - 9:00AM
Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines that address unmet medical needs in central
nervous system (CNS) disorders, today announced the appointment of
Todd S. Young as Executive Vice President, Chief Financial Officer,
effective August 22, 2016. Mr. Young reports to Steve Davis,
ACADIA’s President and Chief Executive Officer.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160824005294/en/
Todd S. Young, Executive Vice President,
Chief Financial Officer of ACADIA Pharmaceuticals (Photo: Business
Wire)
“Todd is a seasoned leader with significant financial and
operational experience in the biopharmaceutical industry,” said
Steve Davis. “His proven finance and leadership skills will be key
as we bring NUPLAZID™ (pimavanserin) to patients in need, seek to
maximize the significant opportunities ahead for pimavanserin, and
deliver on our vision of building a leading CNS company. We welcome
Todd to our team and look forward to his contributions.”
Mr. Young joins ACADIA from Baxalta Incorporated, where he
served as Senior Vice President and Treasurer and played an
integral role as a business leader and in creating the initial
capital structure of Baxalta. Baxalta was acquired by Shire in June
2016. Prior to the acquisition, Baxalta was a global
biopharmaceutical company with $6 billion in revenue that was
formed in July 2015 when Baxter International Inc. spun-out its
biopharmaceutical division. Prior to Baxalta, Mr. Young worked for
over 14 years at Baxter holding multiple leadership roles,
including Corporate Vice President and Treasurer, Vice President,
International Finance, and Vice President, Global Financial
Planning and Analysis (FP&A). Mr. Young’s global FP&A team
was responsible for driving Baxter’s budgeting, forecasting, and
long-range financial planning. As finance leader for Baxter’s
international operations, he led a team of 900 finance members and
helped drive business results and strategic decision making for the
company’s $8 billion international commercial operations.
Early in his career, Mr. Young practiced as a tax attorney at a
major law firm. Mr. Young earned his Bachelor of Arts degree in
Economics from Grinnell College and his Juris Doctor from the
University of Michigan School of Law.
“I am thrilled to join ACADIA,” said Todd Young. “With the
recent commercial launch of NUPLAZID, the company has entered an
exciting new phase. I look forward to executing on ACADIA’s growth
strategy and building long-term value for shareholders.”
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA maintains
a website at www.acadia-pharm.com to which we regularly post copies
of our press releases as well as additional information and through
which interested parties can subscribe to receive e-mail
alerts.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements related to
ACADIA’s plans to bring NUPLAZID™ (pimavanserin) to patients in
need, to maximize opportunities for pimavanserin, and to build a
leading CNS company and shareholder value, as well as potential
contributions of Mr. Young as ACADIA’s Executive Vice President,
Chief Financial Officer. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in
drug discovery, development, approval and commercialization, and in
collaborations with others, and the fact that past results of
clinical trials may not be indicative of future trial results. For
a discussion of these and other factors, please refer to ACADIA’s
annual report on Form 10-K for the year ended December 31, 2015 as
well as ACADIA’s subsequent filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160824005294/en/
Investor Contact:ACADIA Pharmaceuticals Inc.Lisa Barthelemy,
Investor Relations(858) 558-2871ir@acadia-pharm.comorMedia
Contact:Taft and PartnersTed Deutsch(609)
578-8765ted@taftandpartners.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024